NEW

The Joint Commission Promotes Psychosocial Well-being of Health Care Professionals

Health care workers in the U.S. have been facing the COVID-19 pandemic for more than three months now. Stressors such as insufficient personal protective equipment (PPE), fears of infection, feelings of isolation from family, and harassment from the community for...

EA Health and Synergy Surgicalists Announce Business Merger

Synergy Surgicalists – one of the nation's top providers of orthopedic and general surgicalist staffing for hospitals – and EA Health – a leading provider of physician staffing services and specialty physician on-call compensation solutions – have announced a business...

Surgery Exchange Launches Surgery Exchange Network

To cut down on inefficiencies and waste associated with implant procedures, Surgery Exchange is offering enhanced visibility and cost savings to device manufacturers. Surgery Exchange is a specialized suite of software solutions designed to support hospitals with...

SETi Plans Online Sales for Surface Disinfection Device and Portable Air Purifier with Violeds Technology

Sensor Electronic Technology Inc. (“SETi”), the first compound semiconductor for UV LED solutions (Violeds) and Seoul Viosys’ subsidiary, launches portable air purifiers of brand “VAC” and surface disinfection devices of brand “VSM+” with Violeds technology to reduce...

Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue

COMMENCE Trial Four-Year Data Presented at the AATS 99th Annual Meeting

INSPIRIS RESILIA aortic valve

INSPIRIS RESILIA aortic valve

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards’ bioprosthetic surgical aortic valves featuring the company’s novel RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up, with no events of structural valve deterioration (SVD). The COMMENCE study enrolled 694 patients, 144 (21 percent) of which were under the age of 60 when they had surgical valve replacement. The data were presented at the American Association for Thoracic Surgery’s (AATS) 99th annual meeting.

“Patients undergoing valve replacement are living long lives and remaining more active through their later years, increasing the need for advanced valve replacement technologies,” said John D. Puskas, MD, principal investigator for the COMMENCE study. “The absence of structural valve deterioration in these patients is extremely encouraging and highlights the potential of valves containing RESILIA tissue for patients who may otherwise opt for a mechanical valve, which requires long-term use of blood thinning medications.”

Edwards’ innovative and proprietary RESILIA bovine pericardial tissue incorporates a novel integrity-preservation technology that may eliminate a key factor in calcification leading to valve deterioration. The technology also allows the valve to be stored under dry packaging conditions, facilitating ease of use in the operating room.Key findings from the study include:

  • There were no cases of early or late structural valve deterioration or valve thrombosis.
  • Mean transvalvular gradients at 1, 2, 3, and 4 years of follow-up were 10.2±4.6, 10.2±4.5, 10.8±6.0, 11.0±5.6 mm Hg, respectively.

“Edwards takes pride in our ability to innovate new technologies, such as RESILIA tissue, that can help improve long-term patient care and outcomes,” said Daveen Chopra, Edwards’ corporate vice president, surgical structural heart. “The RESILIA tissue platform was created with a vision to extend valve durability for a more active patient population, while reducing the need for long-term use of blood-thinning medication. These encouraging COMMENCE trial data suggest that we are on the path toward realizing that vision.”

The COMMENCE study is a prospective, non-randomized, multicenter, single-arm investigational device exemption (IDE) trial at 27 clinical sites across the United States and Europe. The trial enrolled 694 patients age 18 and older with diagnosed aortic valve disease and scheduled to undergo aortic valve replacement with or without coronary artery bypass graft (CABG). The COMMENCE trial is a PMA-approved study designed to evaluate the safety and effectiveness of surgical aortic heart valves with RESILIA tissue in this patient population for up to five years, with a subset of patients being evaluated through 10 years. At this stage, the study has recorded 2,533 patient-years of follow-up.

Additional five-year data from a European feasibility study of a bioprosthetic aortic valve with RESILIA tissue were presented last month at the Heart Valve Society Annual Meeting. This study, a prospective, single-arm observational clinical trial of 133 patients conducted at two clinical sites in Europe, also yielded positive results. There were no events of structural valve deterioration throughout the study period.

Edwards will further evaluate the novel RESILIA tissue platform through the RESILIENCE trial, a longer-term study that will follow up to 250 patients under the age of 65 who received an Edwards valve with RESILIA tissue. The study will examine calcification levels, hemodynamic deterioration and valve failure at years 5, 7, 9 and 11 as early potential predictors of valve durability.

Dr. Puskas is a consultant to Edwards Lifesciences.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X